Inhibition of SARS-CoV-2 Omicron BA.1 and BA.4 Variants After Fourth Vaccination or Tixagevimab and Cilgavimab Administration in Patients With Cancer.

Maximilian J Mair,Manfred Mitterer,Pia Gattinger,Julia M Berger,Rudolf Valenta,Dominic Fong,Matthias Preusser

JAMA oncology（2022）

引用 3|浏览6

暂无评分

摘要

This cohort study assesses the capacity of passive immunization and tixagevimab and cilgavimab to inhibit interaction between receptor-binding domains and angiotensin-converting enzyme 2 in patients with hemato-oncologic diseases.

查看译文

关键词

fourth vaccination,tixagevimab,cancer,cilgavimab administration,sars-cov

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要